Although preexposure prophylaxis (PrEP) has demonstrated high efficacy for HIV prevention, rates of PrEP uptake remain low among the transgender population, especially in transgender women (TGW). We conducted this scoping review to assess and characterize barriers to PrEP use along the PrEP care continuum among TGW.
Methods
We conducted this scoping review by searching studies in Embase, PubMed, Scopus, and Web of Science. Eligibility criteria included: reporting a PrEP related quantitative result among TGW; peer-reviewed and published in English between 2010-2021.
Results
Globally, high willingness (80%) to use PrEP was found, yet uptake and adherence (35.4%) were low. TGW experiencing hardship, including poverty, incarceration, and substance use, were associated with higher odds of PrEP awareness but lower odds of PrEP use. Structural and social barriers such as stigma, medical mistrust, and perceived racism can be important barriers for PrEP continuation. High social cohesion and hormone replacement therapy were associated with greater odds of awareness. In addition, our study confirmed prior research showing that PrEP does not lower feminizing hormone levels in TGW.
Conclusions
Significant demographic factors among TGW that are associated with PrEP engagement. It is imperative to focus on TGW as a population with independent needs, requiring specific PrEP care guidelines and tailored resource allocation, that fully considers individual-, provider-, and community/structural-level barriers and facilitators. The present review also indicates that combining PrEP care with GAHT or broader gender-affirmation care may facilitate PrEP use.
ReisnerSLPoteatTKeatleyJ, et al.Global health burden and needs of transgender populations: a review. Lancet (London, England)2016; 388(10042): 412–436.
2.
Van GerwenOTJaniALongDM, et al.Prevalence of sexually transmitted infections and human immunodeficiency virus in transgender persons: a systematic review. Transgend Health2020; 5(2): 90–103.
3.
PoteatTReisnerSLRadixA. HIV epidemics among transgender women. Curr Opin HIV AIDS2014; 9(2): 168–173.
4.
BaralSDPoteatTStrömdahlS, et al.Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis2013; 13(3): 214–222.
5.
SeveliusJMPoteatTLuhurWE, et al.HIV testing and PrEP use in a national probability sample of sexually active transgender people in the United States. J Acquir Immune Defic Syndr2020; 84(5): 437–442.
6.
McCormackSDunnDTDesaiM, et al.Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet (London, England)2016; 387(10013): 53–60.
7.
MolinaJ-MCharreauISpireB, et al.Efficacy, safety, and effect on sexual behaviour of on-demand preexposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV2017; 4(9): e402–e410.
8.
LaurentCDembélé KeitaBYayaI, et al.HIV preexposure prophylaxis for men who have sex with men in West Africa: a multicountry demonstration study. Lancet HIV2021; 8: e420.
9.
MayerKHAgwuAMalebrancheD. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther2020; 37(5): 1778–1811.
10.
PoteatTGermanDFlynnC. The conflation of gender and sex: gaps and opportunities in HIV data among transgender women and MSM. Glob Public Health2016; 11(7–8): 835–848. DOI: 10.1080/17441692.2015.1134615.
11.
Van GriensvenFde Lind van WijngaardenJWEustaquioPC, et al.The continuing HIV epidemic among men who have sex with men and transgender women in the ASEAN region: implications for HIV policy and service programming. Sex Health2021; 18: 21.
12.
NietoOBrooksRALandrianA, et al.PrEP discontinuation among latino/a and black MSM and transgender women: a need for PrEP support services. PLoS One2020; 15(11): e0241340.
13.
EzenniaOGeterASmithDK. The PrEP care continuum and black men who have sex with men: a scoping review of published data on awareness, uptake, adherence, and retention in PrEP care. AIDS Behav2019; 23(10): 2654–2673.
ArkseyHO’MalleyL. Scoping studies: towards a methodological framework. Int J Soc Res2005; 8(1): 19–32.
16.
TriccoACLillieEZarinW, et al.PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med2018; 169(7): 467–473.
17.
OuzzaniMHammadyHFedorowiczZ, et al.Rayyan—a web and mobile app for systematic reviews. Syst Rev2016; 5: 210. DOI: 10.1186/s13643-016-0384-4.
18.
AndrzejewskiJDunvilleRJohnsMM, et al.Medical gender affirmation and HIV and sexually transmitted disease prevention in transgender youth: results from the survey of today’s adolescent relationships and transitions 2018. LGBT Health2021; 8(3): 181–189. DOI: 10.1089/lgbt.2020.0367.
19.
CirrincioneLRPodanyATHavensJP, et al.Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. J Antimicrob Chemother2020; 75(5): 1242–1249. DOI: 10.1093/jac/dkaa016.
20.
ClarkJReisnerSPerez-BrumerA, et al.TransPrEP: results from the pilot study of a social network-based intervention to support PrEP adherence among transgender women in Lima, Peru. AIDS Behav2021; 25(6): 1873–1883. DOI: 10.1007/s10461-020-03117-4.
21.
D'AvanzoPABassSBBrajuhaJ, et al.Medical mistrust and PrEP perceptions among transgender women: a cluster analysis. Behav Med (Washington, DC)2019; 45(2): 143–152.
22.
D'AvanzoPABassSBKellyPJ, et al.Community belonging and attitudes towards HIV pre-exposure prophylaxis (PrEP) among transgender women. AIDS Behav2021; 25(9): 2728–2742. DOI: 10.1007/s10461-021-03183-2.
23.
DeutschMBGliddenDVSeveliusJ, et al.HIV preexposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV2015; 2(12): e512–e519. DOI: 10.1016/S2352-3018(15)00206-4.
24.
FisherCBFriedALDesmondM, et al.Facilitators and barriers to participation in PrEP HIV prevention trials involving transgender male and female adolescents and emerging adults. AIDS Educ Prev2017; 29(3): 205–217. DOI: 10.1521/aeap.2017.29.3.205.
25.
GalkaJMWangMAzwaI, et al.Willingness to use pre-exposure prophylaxis (PrEP) for HIV prevention and PrEP implementation preferences among transgender women in Malaysia. Transgend Health2020; 5(4): 258–266. DOI: 10.1089/trgh.2020.0003.
26.
GrantRMPellegriniMDefechereuxPA, et al.Sex hormone therapy and tenofovir diphosphate concentration in dried blood spots: primary results of the interactions between antiretrovirals and transgender hormones study. Clin Infect Dis2021; 73(7): e2117–e2123. DOI: 10.1093/cid/ciaa1160.
27.
HiransuthikulAJanamnuaysookRHimmadK, et al.Drug-drug interactions between feminizing hormone therapy and preexposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc2019; 22(7): e25338. DOI: 10.1002/jia2.25338.
28.
HolderCLPerez-GilbeHRFajardoFJ, et al.Disparities of HIV risk and PrEP use among transgender women of color in South Florida. J Natl Med Assoc2019; 111(6): 625–632. DOI: 10.1016/j.jnma.2019.08.001.
29.
HoodJEEljalladTAbadJ, et al.Getting preexposure prophylaxis to high-risk transgender women: lessons from Detroit, USA. Sex Health2018; 15(6): 562–569. DOI: 10.1071/SH18063.
30.
JalilEMGrinsztejnBVelasqueL, et al.Awareness, willingness, and PrEP eligibility among transgender women in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr2018; 79(4): 445–452. DOI: 10.1097/QAI.0000000000001839.
31.
KimaniMvan der ElstEMChiroO, et al.PrEP interest and HIV-1 incidence among MSM and transgender women in coastal Kenya. J Int AIDS Soc2019; 22(6): e25323. DOI: 10.1002/jia2.25323.
32.
KimaniMvan der ElstEMChirroO, et al.“I wish to remain HIV negative”: preexposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya. PLoS One2021; 16(1): e0244226. DOI: 10.1371/journal.pone.0244226.
33.
KrakowerDMaloneyKMPowellVE, et al.Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. J Int AIDS Soc2019; 22(2): e25250. DOI: 10.1002/jia2.25250.
34.
PhanuphakNSungsingTJantarapakdeJ, et al.Princess PrEP program: the first key population-led model to deliver preexposure prophylaxis to key populations by key populations in Thailand. Sex Health2018; 15(6): 542–555. DOI: 10.1071/SH18065.
35.
PoteatTMalikMvan der MerweLL, et al.PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study. Lancet HIV2020; 7(12): e825–e834.
36.
PoteatTWirtzAMalikM, et al.A gap between willingness and uptake: findings from mixed methods research on HIV prevention among black and latina transgender women. J Acquir Immune Defic Syndr2019; 82(2): 131–140. DOI: 10.1097/QAI.0000000000002112.
37.
PyraMRusieLKBakerKK, et al.Correlations of HIV preexposure prophylaxis indications and uptake, Chicago, Illinois, 2015–2018. Am J Public Health2020; 110(3): 370–377. DOI: 10.2105/AJPH.2019.305469.
38.
RamautarsingRAMeksenaRSungsingT, et al.Evaluation of a preexposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens. J Int AIDS Soc2020; 23(Suppl 3): e25540. DOI: 10.1002/jia2.25540.
39.
RebackCJClarkKARüngerD, et al.A promising PrEP navigation intervention for transgender women and men who have sex with men experiencing multiple syndemic health disparities. J Community Health2019; 44(6): 1193–1203. DOI: 10.1007/s10900-019-00705-x.
40.
ReisnerSLJadwin-CakmakLWhite HughtoJM, et al.Characterizing the HIV prevention and care continua in a sample of transgender youth in the US. AIDS Behav2017; 21(12): 3312–3327. DOI: 10.1007/s10461-017-1938-8.
41.
RestarAJAdiaACu-UvinS, et al.Characterizing PrEP awareness and interest among filipina transgender women. AIDS Educ Prev2020; 32(3): 212–228. DOI: 10.1521/aeap.2020.32.3.212.
42.
RestarAJKuhnsLReisnerSL, et al.Acceptability of antiretroviral pre-exposure prophylaxis from a cohort of sexually experienced young transgender women in two US cities. AIDS Behav2018; 22(11): 3649–3657. DOI: 10.1007/s10461-018-2127-0.
43.
ScottHMSpinelliMVittinghoffE, et al.Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. AIDS2019; 33(14): 2189–2195. DOI: 10.1097/QAD.0000000000002347.
44.
SeekaewPNguyenESungsingT, et al.Correlates of nonadherence to key population-led HIV preexposure prophylaxis services among Thai men who have sex with men and transgender women. BMC Public Health2019; 19(1): 328. DOI: 10.1186/s12889-019-6645-0.
45.
SeekaewPPengnonyangSJantarapakdeJ, et al.Discordance between self-perceived and actual risk of HIV infection among men who have sex with men and transgender women in Thailand: a cross-sectional assessment. J Int AIDS Soc2019; 22(12): e25430. DOI: 10.1002/jia2.25430.
46.
ShiehEMarzinkeMAFuchsEJ, et al.Transgender women on oral HIV preexposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc2019; 22(11): e25405. DOI: 10.1002/jia2.25405.
47.
SoaresFMacCarthySMagnoL, et al.Factors associated with PrEP refusal among transgender women in Northeastern Brazil. AIDS Behav2019; 23(10): 2710–2718. DOI: 10.1007/s10461-019-02501-z.
48.
WangZLauJTFYangX, et al.Acceptability of daily use of free oral pre-exposure prophylaxis (PrEP) among transgender women sex workers in Shenyang, China. AIDS Behav2017; 21(12): 3287–3298. DOI: 10.1007/s10461-017-1869-4.
49.
WilsonECJinHLiuA, et al.Knowledge, indications and willingness to take preexposure prophylaxis among transwomen in San Francisco, 2013. PLoS One2015; 10(6): e0128971. DOI: 10.1371/journal.pone.0128971.
50.
WilsonECJalilEMMoreiraRI, et al.High risk and low HIV prevention behaviours in a new generation of young trans women in Brazil. AIDS Care2021; 33(8): 997–1001. DOI: 10.1080/09540121.2020.1844859.
51.
WilsonECTurnerCMArayasirikulS, et al.Disparities in the PrEP continuum for trans women compared to MSM in San Francisco, California: results from population-based cross-sectional behavioural surveillance studies. J Int AIDS Soc2020; 23(Suppl 3): e25539. DOI: 10.1002/jia2.25539.
52.
YanLYanZWilsonE, et al.Awareness and willingness to use HIV pre-exposure prophylaxis (PrEP) among trans women in China: a community-based survey. AIDS Behav2021; 25(3): 866–874. DOI: 10.1007/s10461-020-03050-6.
53.
YangDChariyalertsakCWongthaneeA, et al.Acceptability of preexposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. PLoS One2013; 8(10): e76650. DOI: 10.1371/journal.pone.0076650.
54.
ZalazarVArísteguiIKerrT, et al.High willingness to use HIV pre-exposure prophylaxis among transgender women in Argentina. Transgend Health2016; 1(1): 266–273. DOI: 10.1089/trgh.2016.0033.
55.
ZarwellMJohnSAWestmorelandD, et al.PrEP uptake and discontinuation among a US national sample of transgender men and women. AIDS Behav2021; 25(4): 1063–1071. DOI: 10.1007/s10461-020-03064-0.
56.
OldenburgCELeBToanT, et al.HIV pre-exposure prophylaxis indication and readiness among HIV-uninfected transgender women in Ho Chi Minh City, Vietnam. AIDS Behav2016; 20(Suppl 3): 365–370. DOI: 10.1007/s10461-016-1483-x.
57.
KannyDJeffriesWL IVChapin-BardalesJ, et al.Racial/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men — 23 urban areas, 2017. MMWR Morb Mortal Wkly Rep2019; 68: 801–806.
58.
ChanPASeilerNChuCT. Leveraging medicaid to enhance preexposure prophylaxis implementation efforts and ending the HIV epidemic. Am J Public Health2020; 110(1): 65–66.
59.
EdmistonEKDonaldCASattlerAR, et al.Opportunities and gaps in primary care preventative health services for transgender patients: a systematic review. Transgend Health2016; 1(1): 216–230.
60.
MarzinkeMAGrinsztejnBFogelJM, et al.Characterization of human immunodeficiency virus (HIV) Infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis2021; 224(9): 1581–1592. DOI: 10.1093/infdis/jiab152.
61.
SaberiPScottHM. On-demand oral pre-exposure prophylaxis with tenofovir/emtricitabine: what every clinician needs to know. J Gen Intern Med2020; 35(4): 1285–1288. DOI: 10.1007/s11606-020-05651-2.
62.
RaifmanJNockaKGalárragaO, et al.Evaluating statewide HIV preexposure prophylaxis implementation using all-payer claims data. Ann Epidemiol2020; 44: 1.e2–7.e2. DOI: 10.1016/j.annepidem.2020.03.003.
63.
DowningJYeeKSeveliusJM. PrEP use and adherence among transgender patients. AIDS Behav2022; 26: 1251–1259. DOI: 10.1007/s10461-021-03482-8.
64.
NemotoTBödekerBIwamotoM. Social support, exposure to violence and transphobia, and correlates of depression among male-to-female transgender women with a history of sex work. Am J Public Health2011; 101(10): 1980–1988.
65.
SaferJDColemanEFeldmanJ, et al.Barriers to healthcare for transgender individuals. Curr Opin Endocrinol Diabetes Obes2016; 23(2): 168–171.
66.
LefevorGTBoyd-RogersCCSpragueBM, et al.Health disparities between genderqueer, transgender, and cisgender individuals: an extension of minority stress theory. J Couns Psychol2019; 66(4): 385–395.
67.
SeveliusJMKeatleyJCalmaN, et al.‘I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health2016; 11(7–8): 1060–1075.
68.
RaelCTMartinezMGiguereR, et al.Barriers and facilitators to oral PrEP use among transgender women in New York city. AIDS Behav2018; 22(11): 3627–3636. DOI: 10.15585/mmwr.mm6837a2externalicon.
